Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Sarfaty M, Whiting K, Teo MY, Lee CH, Peters V, Durocher J, Regazzi AM, McCoy AS, Hettich G, Jungbluth AA, Al-Ahmadie H, Ostrovnaya I, Chaim J, Bajorin DF, Rosenberg JE, Iyer G, Funt SA. Sarfaty M, et al. Cancer Med. 2021 Feb;10(3):1074-1083. doi: 10.1002/cam4.3699. Epub 2020 Dec 31. Cancer Med. 2021. PMID: 33382520 Free PMC article. Clinical Trial.
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, Lee CH, Aggen DH, Regazzi AM, Chen Z, Lattanzi M, Al-Ahmadie HA, Brannon AR, Shah R, Chu C, Lenis AT, Pietzak E, Bochner BH, Berger MF, Solit DB, Rosenberg JE, Bajorin DF, Iyer G. Guercio BJ, et al. Among authors: sarfaty m. Clin Cancer Res. 2023 Nov 14;29(22):4586-4595. doi: 10.1158/1078-0432.CCR-23-1283. Clin Cancer Res. 2023. PMID: 37682528 Free PMC article.
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.
Iyer G, Tangen CM, Sarfaty M, Regazzi AM, Lee IL, Fong M, Choi W, Dinney CPN, Flaig TW, Thompson IM Jr, Lerner SP, McConkey DJ, Rosenberg JE. Iyer G, et al. Among authors: sarfaty m. JCO Precis Oncol. 2024 Nov;8:e2400287. doi: 10.1200/PO.24.00287. Epub 2024 Nov 5. JCO Precis Oncol. 2024. PMID: 39499893
Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.
Rouvinov K, Levanon E, Peer A, Sarfaty M, Sarid D, Neiman V, Grikshtas E, Rosenbaum E, Kushnir I, Talmor B, Friger M, Zarbiv Y, Gez E, Dresler H, Shalata W, Meirovitz A, Shrem NS, Yakobson A, Mermershtain W, Keizman D. Rouvinov K, et al. Among authors: sarfaty m. Front Oncol. 2023 May 24;13:1151701. doi: 10.3389/fonc.2023.1151701. eCollection 2023. Front Oncol. 2023. PMID: 37293597 Free PMC article.
86 results